Last C$0.07 CAD
Change Today +0.005 / 7.69%
Volume 20.0K
QPT On Other Exchanges
Symbol
Exchange
Venture
OTC US
As of 1:32 PM 04/15/14 All times are local (Market data is delayed by at least 15 minutes).

quest pharmatech inc (QPT) Snapshot

Open
C$0.07
Previous Close
C$0.07
Day High
C$0.07
Day Low
C$0.07
52 Week High
12/12/13 - C$0.10
52 Week Low
05/10/13 - C$0.03
Market Cap
7.1M
Average Volume 10 Days
7.0K
EPS TTM
C$-0.03
Shares Outstanding
101.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for QUEST PHARMATECH INC (QPT)

Related News

No related news articles were found.

quest pharmatech inc (QPT) Related Businessweek News

No Related Businessweek News Found

quest pharmatech inc (QPT) Details

Quest PharmaTech Inc., a clinical stage biotechnology company, engages in the development and commercialization of oncology products. It develops a portfolio of product candidates for the treatment of cancer by combining immunotherapeutic antibodies with chemotherapy, immune-adjuvants, and photodynamic therapy. The company's lead product candidate, Oregovomab, an immunotherapeutic product for the treatment of ovarian cancer and is under a multi-center Phase IIb clinical trials in Italy and the United States. The company also develops MUC1 program that has completed phase I clinical trials for the treatment of cancer tumors; and SL052, a photosensitizer product, which is under phase I clinical trials and is intended for the treatment of prostate cancer. Quest PharmaTech Inc. has a strategic relationship with with AD Biotech Co., Ltd. The company is headquartered in Edmonton, Canada.

quest pharmatech inc (QPT) Top Compensated Officers

Chief Executive Officer, Director, Ex-Officio...
Total Annual Compensation: C$150.0K
Chief Financial Officer
Total Annual Compensation: C$100.0K
Vice President of Product Development
Total Annual Compensation: C$126.0K
Compensation as of Fiscal Year 2013.

quest pharmatech inc (QPT) Key Developments

Quest PharmaTech, Inc. Announces Third Combinatorial Immunotherapy Clinical Trial for Oregovomab with a TLR3 agonist, Hiltonol

Quest PharmaTech Inc. announced that is has entered into a license agreement with Oncovir, Inc. (Washington, DC) to evaluate the clinical utility of combining Quest's antibody immunotherapy technology with Oncovir's immune activator "Hiltonol(R) " in a twenty patient ovarian cancer Phase II clinical trial. The trial will be conducted in Rome, Italy under the direction of Professor Roberto Angioli of University Bio Medico. Oncovir will provide the needed drug, appropriate technical expertise and relevant data to support the regulatory process necessary to conduct the clinical trial. Hiltonol(R) (Poly ICLC) is a TLR-3 agonist that has been shown to have specific anti-tumor and anti-viral actions. It is emerging as a promising component to enhance activity of multiple cancer and HIV vaccines. As a result, Oncovir currently has over two dozen recently completed or ongoing Phase I or II investigator initiated, collaborative clinical trials, using Hiltonol(R) alone or in combination with other agents. Several hundred patients have been safely treated to date and another dozen trials are in various stages of planning or submission. This planned clinical study is part of Quest's strategy of conducting three risk mitigating clinical trials with Oregovomab in combination with chemotherapy to confirm its ability to generate a clinically meaningful antigen specific T-cell response in both ovarian cancer patients, and also other CA125 associated cancer settings, such as select patients with pancreatic cancer. Quest seeks to optimize the utility of cancer immunotherapy through artful combination of its antibodies with cytotoxic agents and promising additional immune adjuvants. The first two clinical trials in this initiative are already underway at clinical centers in Italy and the U.S.

Quest PharmaTech, Inc. Presents at 12th Annual BIO Investor Forum, Oct-08-2013

Quest PharmaTech, Inc. Presents at 12th Annual BIO Investor Forum, Oct-08-2013 . Venue: The Palace Hotel, 2 New Montgomery Street, San Francisco, CA 94105, United States.

Quest PharmaTech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended July 31, 2013

Quest PharmaTech Inc. reported earnings results for the second quarter and six months ended July 31, 2013. For the quarter, the company's net and comprehensive loss was CAD 640,126, or CAD 0.008 loss per share, compared to a net and comprehensive loss of CAD 433,923, or CAD 0.005 loss per share, for the same quarter ended July 31, 2012. Financial income was CAD 65, compared to CAD 112 for the same quarter ended July 31, 2012. For the six months, the company's net and comprehensive loss was CAD 1.02 million, or CAD 0.012 loss per share, compared to a net and comprehensive loss of CAD 743,314, or CAD 0.009 loss per share, for the same period ended July 31, 2012. Financial income was CAD 65, compared to CAD 217 for the same quarter ended July 31, 2012.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QPT:CN C$0.07 CAD +0.005

QPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for QPT.
View Industry Companies
 

Industry Analysis

QPT

Industry Average

Valuation QPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUEST PHARMATECH INC, please visit www.questpharmatech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.